Samuel J Klempner
HS Assistant Professor, Medicine
School of Medicine
School of Medicine
Fellowship -- Hematology-Oncology, Beth Israel Deaconess Medical Center/Harvard Medical School, 2013
Residency -- Internal Medicine, Brigham and Women's Hospital/Harvard Medical School, 2010
MD -- University of Massachusetts Medical School, 2007
BA -- Hamilton College, 2003
Residency -- Internal Medicine, Brigham and Women's Hospital/Harvard Medical School, 2010
MD -- University of Massachusetts Medical School, 2007
BA -- Hamilton College, 2003
University of California, Irvine
101 The City Drive South
Building 56
Room 242
Mail Code: 4061
Orange, CA 92868
101 The City Drive South
Building 56
Room 242
Mail Code: 4061
Orange, CA 92868
Research Interests
Gastric Cancer, Esophageal Cancer, Phase I-II, Drug Resistance, Targeted Therapy, Drug Development, Molecular Classification
Research Abstract
I am interested in novel targeted therapies for advanced solid tumors with a particular focus on strategies to delay and overcome acquired resistance.
Publications
Publications:
1. Klempner SJ, Cohen DW, Costa DB. ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers. J Thorac Oncol. 2011 Aug; 6(8):1439-40. PMID: 21847065
2. Selby KJ, Warner J, Klempner S, Konstantinopoulos PA, Hecht JL. Anti-Yo antibody associated with occult fallopian tube carcinoma. Int J Gynecol Pathol. 2011 Nov; 30(6):536-8. PMID: 21979588
3. Klempner SJ, Choueiri TK,Yee E, Doyle L, Schuppan D, Atkins MB. Pazopanib Induced Hepatotoxicity: Two Cases with Histologic Correlation. J Clin Oncol. 2012;30(27):e264-268. PMID: 22802316
4. Klempner SJ, Bubley G. Complementary and Alternative Medicines in Prostate Cancer: From Bench to Bedside? Oncologist. 2012;17(6):830-837. PMID: 22618569
5. Klempner SJ, Costa DB, Wu P, Ariyabuddhiphongs K. Safety of Cupping During Bevacizumab Therapy. J Altern Complement Med. 2013;19(8):729-31. PMID: 23379829
6. Klempner SJ, Myers AP, Mills GB, Westin, S. Clinical Investigation of Receptor and Non-Receptor Tyrosine Kinase Inhibitors for the Treatment of Epithelial Ovarian Cancer. Expert Opin Pharmacother. 2013 Nov;14(16):2171-82, PMID: 23937415).
7. Klempner SJ, Myers AP, Cantley LC. What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the PI3K/AKT/mTOR Pathway. Cancer Discov. 2013 Dec;3(12):1345-54, PMID: 24265156
8. Westin S, Ju Z, Broaddus R, Krakstad C, Li J, Pal N, Lu K, Hennessy B, Klempner SJ, Werner H, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent determinant of patient outcomes in obese and non-obese endometrioid endometrial cancer patients. (Under Review, Journal of Clinical Investigation)
9. Ou SH, Azada M, Hsiang D, Herman J, Kain T, Siwak-Tapp C, Casey C, He J, Ali S, Klempner SJ, Miller VA. Next generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014;9:549-553. PMID 24736079
10. Yang W, Raufi A, Klempner SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta 2014;1846:232-237. PMID 24858418.
11. Raufi A, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: Preclinical rationale and early clinical investigations. (Accepted, Journal Gastrointestinal Oncology).
12. Klempner SJ, Aubin G, Dash A, Ou SH. Spontaneous Regression of Crizotinib-Associated Complex Renal Cysts During Continuous Crizotinib Treatment. Oncologist 2014;19:1008-1010. PMID 25096999
13. Ou SH, Klempner SJ, Greenbowe J, et al. Identification of a Novel HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib. J Thorac Oncol 2014;9:1821-5. PMID 25393796
14. Ali SM, Sanford E, Klempner SJ, Rubinson D, Wang K, Palmer N, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci D, Braiteh F, Erlich R, Stephens PJ, Ross JS, Ou I S-H, Miller VA. Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Reveals Frequent Clinically Relevant Genomic Alterations and New Routes to Targeted Therapies. Oncologist 2015 [Epub ahead of print]. PMID 25882375
15. Klempner SJ, Ou SH, Costa DB, et al. The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases from Synchronous Primaries in Non-Small Cell Lung Cancer: A Mini-Review. (Accepted 3/2015, Clinical Lung Cancer).
16. Ou SH, Klempner SJ, Azada M, Rausei-Mills V, Duma C. Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management. Lung Cancer 2015 [Epub ahead of print] PMID 25882777
17. Klempner SJ, Ou, SH. ROS1 (c-ros oncogene 1). Atlas Genet Cytogenet Oncol Haematol. January 2014. URL: http://atlasgeneticsoncology.org/Genes/GC_ROS1.html
Abstracts:
1. Klempner SJ, Miller SA. Apoptosis plays a role in removal of the first and second aortic arch arteries, in remodeling of the thyroid rudiment and in rupture of closing plates in chick embryos. 62nd Annual Society of Developmental Biology Meeting, 8/1/2003, Boston, MA, Developmental Biology 259: 588 Abstract #652.
2. Miller SA, Campbell C, Ransom E, Klempner SJ. Apoptosis precedes removal of avian thyroglossal duct and suggests cell culling in early bilobed thyroid. Experimental Biology, 4/21/2004, Washington D.C., FASEB late-breaking abstracts program.
3. Klempner SJ, Myers AP, Li J, Mills G, Cantley L. Derivation and characterization of endometrial cancer cells resistant to phosphatidylinositol-3-kinase (PI3K) pathway inhibitors. AACR Annual Meeting, 4/2013, Washington, D.C. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. Abstract #4265.
4. Ju Z, Westin S, Broaddus R, Li J, Pal N, Lu K, Coleman RL, Klempner S, Cantley LC, Mills GB, Myers AP. PTEN loss is a context dependent determinant of patient outcomes in obese and non-obese endometrioid endometrial cancer patients. ASCO Annual Meeting, 6/2013, Chicago, IL, J Clin Oncol 31, 2013 (suppl; abstr 5521).
Book Chapters:
1. Klempner SJ, Vo T, Myers AP, Cantley LC. The Phosphatidylinositol 3-kinase Pathway in Human Malignancy. In Kurzrock R, Anderson KC and Tsimberidou AM (eds), Targeted Therapy in Cancer (2015). Wiley: New York. ISBN 9781118468579
2. Yun J, Poulogiannis G, Brown E, Klempner S, Cantley LC. Molecular Pathogenesis of Colorectal Cancer. The PI3K Pathway in Colorectal Cancer. K.M. Haigis ed. Springer New York 2013 (Publication date 11/15/2013, ISBN-13: 9781461484110).
1. Klempner SJ, Cohen DW, Costa DB. ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers. J Thorac Oncol. 2011 Aug; 6(8):1439-40. PMID: 21847065
2. Selby KJ, Warner J, Klempner S, Konstantinopoulos PA, Hecht JL. Anti-Yo antibody associated with occult fallopian tube carcinoma. Int J Gynecol Pathol. 2011 Nov; 30(6):536-8. PMID: 21979588
3. Klempner SJ, Choueiri TK,Yee E, Doyle L, Schuppan D, Atkins MB. Pazopanib Induced Hepatotoxicity: Two Cases with Histologic Correlation. J Clin Oncol. 2012;30(27):e264-268. PMID: 22802316
4. Klempner SJ, Bubley G. Complementary and Alternative Medicines in Prostate Cancer: From Bench to Bedside? Oncologist. 2012;17(6):830-837. PMID: 22618569
5. Klempner SJ, Costa DB, Wu P, Ariyabuddhiphongs K. Safety of Cupping During Bevacizumab Therapy. J Altern Complement Med. 2013;19(8):729-31. PMID: 23379829
6. Klempner SJ, Myers AP, Mills GB, Westin, S. Clinical Investigation of Receptor and Non-Receptor Tyrosine Kinase Inhibitors for the Treatment of Epithelial Ovarian Cancer. Expert Opin Pharmacother. 2013 Nov;14(16):2171-82, PMID: 23937415).
7. Klempner SJ, Myers AP, Cantley LC. What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the PI3K/AKT/mTOR Pathway. Cancer Discov. 2013 Dec;3(12):1345-54, PMID: 24265156
8. Westin S, Ju Z, Broaddus R, Krakstad C, Li J, Pal N, Lu K, Hennessy B, Klempner SJ, Werner H, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent determinant of patient outcomes in obese and non-obese endometrioid endometrial cancer patients. (Under Review, Journal of Clinical Investigation)
9. Ou SH, Azada M, Hsiang D, Herman J, Kain T, Siwak-Tapp C, Casey C, He J, Ali S, Klempner SJ, Miller VA. Next generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014;9:549-553. PMID 24736079
10. Yang W, Raufi A, Klempner SJ. Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta 2014;1846:232-237. PMID 24858418.
11. Raufi A, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: Preclinical rationale and early clinical investigations. (Accepted, Journal Gastrointestinal Oncology).
12. Klempner SJ, Aubin G, Dash A, Ou SH. Spontaneous Regression of Crizotinib-Associated Complex Renal Cysts During Continuous Crizotinib Treatment. Oncologist 2014;19:1008-1010. PMID 25096999
13. Ou SH, Klempner SJ, Greenbowe J, et al. Identification of a Novel HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib. J Thorac Oncol 2014;9:1821-5. PMID 25393796
14. Ali SM, Sanford E, Klempner SJ, Rubinson D, Wang K, Palmer N, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci D, Braiteh F, Erlich R, Stephens PJ, Ross JS, Ou I S-H, Miller VA. Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Reveals Frequent Clinically Relevant Genomic Alterations and New Routes to Targeted Therapies. Oncologist 2015 [Epub ahead of print]. PMID 25882375
15. Klempner SJ, Ou SH, Costa DB, et al. The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases from Synchronous Primaries in Non-Small Cell Lung Cancer: A Mini-Review. (Accepted 3/2015, Clinical Lung Cancer).
16. Ou SH, Klempner SJ, Azada M, Rausei-Mills V, Duma C. Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management. Lung Cancer 2015 [Epub ahead of print] PMID 25882777
17. Klempner SJ, Ou, SH. ROS1 (c-ros oncogene 1). Atlas Genet Cytogenet Oncol Haematol. January 2014. URL: http://atlasgeneticsoncology.org/Genes/GC_ROS1.html
Abstracts:
1. Klempner SJ, Miller SA. Apoptosis plays a role in removal of the first and second aortic arch arteries, in remodeling of the thyroid rudiment and in rupture of closing plates in chick embryos. 62nd Annual Society of Developmental Biology Meeting, 8/1/2003, Boston, MA, Developmental Biology 259: 588 Abstract #652.
2. Miller SA, Campbell C, Ransom E, Klempner SJ. Apoptosis precedes removal of avian thyroglossal duct and suggests cell culling in early bilobed thyroid. Experimental Biology, 4/21/2004, Washington D.C., FASEB late-breaking abstracts program.
3. Klempner SJ, Myers AP, Li J, Mills G, Cantley L. Derivation and characterization of endometrial cancer cells resistant to phosphatidylinositol-3-kinase (PI3K) pathway inhibitors. AACR Annual Meeting, 4/2013, Washington, D.C. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; 2013. Abstract #4265.
4. Ju Z, Westin S, Broaddus R, Li J, Pal N, Lu K, Coleman RL, Klempner S, Cantley LC, Mills GB, Myers AP. PTEN loss is a context dependent determinant of patient outcomes in obese and non-obese endometrioid endometrial cancer patients. ASCO Annual Meeting, 6/2013, Chicago, IL, J Clin Oncol 31, 2013 (suppl; abstr 5521).
Book Chapters:
1. Klempner SJ, Vo T, Myers AP, Cantley LC. The Phosphatidylinositol 3-kinase Pathway in Human Malignancy. In Kurzrock R, Anderson KC and Tsimberidou AM (eds), Targeted Therapy in Cancer (2015). Wiley: New York. ISBN 9781118468579
2. Yun J, Poulogiannis G, Brown E, Klempner S, Cantley LC. Molecular Pathogenesis of Colorectal Cancer. The PI3K Pathway in Colorectal Cancer. K.M. Haigis ed. Springer New York 2013 (Publication date 11/15/2013, ISBN-13: 9781461484110).
Professional Societies
American Society of Clinical Oncology (ASCO)
American Association for Cancer Research (AACR)
Other Experience
Research Fellow (PI Dr. Lewis C. Cantley)
Harvard Medical School 2011—2013
Harvard Medical School 2011—2013
Graduate Programs
Hematology and Oncology (IM)
Internal Medicine
Link to this profile
https://faculty.uci.edu/profile/?facultyId=5981
https://faculty.uci.edu/profile/?facultyId=5981
Last updated
04/24/2015
04/24/2015